Lotus Eye Hospital and Institute LimitedLOTUSEYECorporate

Healthcare Latest results: Jun 2026 2 quarters of data
₹114.36
MCap ₹243 Cr
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹17 Cr
Sales · Jun 2026
₹3 Cr
Operating Profit · Jun 2026
17.3%
OPM % · Jun 2026
₹1 Cr
Net Profit · Jun 2026
₹0.30
EPS · Jun 2026

📝 Lotus Eye Hospital and Institute Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Lotus Eye Hospital and Institute Limited reported revenue of ₹17 crore for the quarter ended June 2026 (Q1 FY27).

Net profit stood at ₹1 crore. Earnings per share (EPS) came in at ₹0.30.

Operating profit stood at ₹3 crore — an operating margin (OPM) of 17.3%.

Valuation snapshot

At the current price of ₹114.36, LOTUSEYE has a market capitalisation of ₹243 crore.

Within the Healthcare industry, it is the 15th-largest of the 22 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 40.14%, domestic institutional investors (DIIs) 0.02%, public shareholders 59.85% of Lotus Eye Hospital and Institute Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹243 Cr
Current Price ?
₹114.4
P/E ?
N/A
Industry P/E ?
34.70
P/B ?
4.04
P/S ?
N/A
P/FCF ?
-24.29
Enterprise Value ?
₹259 Cr
EV/EBITDA ?
N/A
PEG ?
N/A
Earnings Yield ?
N/A
Dividend Yield ?
N/A
Profitability & Returns
Sales (TTM) ?
N/A
OPM ?
N/A
Profit after tax (TTM) ?
N/A
EPS (TTM) ?
N/A
ROCE ?
1.2%
ROE ?
N/A
ROA ?
N/A
Growth
Sales — latest qtr ?
₹17 Cr
PAT — latest qtr ?
₹1 Cr
YoY qtr sales growth ?
N/A
YoY qtr profit growth ?
N/A
Sales growth (3y) ?
N/A
Sales growth (5y) ?
N/A
Profit growth (3y) ?
N/A
Profit growth (5y) ?
N/A
Financial Health
Debt ?
₹16 Cr
Debt to Equity ?
0.26
Interest Coverage ?
N/A
Current Ratio ?
N/A
Ownership
Promoter holding ?
40.14%
Change in promoter holding ?
-0.25%
Pledged percentage ?
N/A
Market
Return 3 months ?
-6.3%
Return 6 months ?
2.6%

🗓️ Quarterly results (2 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Dec 2025Jun 2026 YoY % QoQ %
Sales 1417 — —
Operating Profit 13 — —
Other Income 00 — —
Interest 01 — —
Depreciation 12 — —
Profit Before Tax -01 — —
Net Profit -01 — —
EPS -0.130.30 — —
OPM % 4.8% 17.3% — —

📆 Annual results (₹ Cr, FY = Apr–Mar)

Annual rollup not yet available We need at least 3 quarters of a fiscal year to compute annual figures. This symbol does not yet have a complete fiscal year in our database.

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 20.8020.8020.8020.80 +0.0%
Reserves 36.7838.6139.2039.34 +0.4%
Borrowings 0.671.113.4315.83 +361.5%
Other Liabilities 4.936.116.146.63 +8.0%
Total Liabilities 63.1866.6369.5782.60 +18.7%
Fixed Assets 44.1848.6554.0765.81 +21.7%
CWIP 0.000.080.000.09 —
Investments 0.000.000.000.00 —
Other Assets 19.0017.9015.5016.70 +7.7%
Total Assets 63.1866.6369.5782.60 +18.7%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 4.395.682.703.02 +11.9%
Cash from Investing Activity -2.19-4.63-6.13-12.37 -101.8%
Cash from Financing Activity -1.71-3.40-1.609.03 +664.4%
Net Cash Flow 0.49-2.35-5.03-0.32 +93.6%
Free Cash Flow 1.300.10-2.09-10.01 -378.9%
CFO/OP 76%101%94%99% +5.3%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 9.089.549.728.22 -15.4%
Inventory Days 153.60170.30193.6284.01 -56.6%
Days Payable 173.42183.56169.8671.29 -58.0%
Cash Conversion Cycle -10.74-3.7233.4820.95 -37.4%
Working Capital Days 8.615.680.00-12.23 —
ROCE % 10.25%7.07%2.99%1.16% -61.2%

👥 Shareholding (latest 5 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026Sep 2026 % Chg
Promoters 40.39%40.63%40.66%40.14%40.14% +0.0%
FIIs 0.01%0.00%0.01%0.00%— —
DIIs 0.02%0.02%0.02%0.02%0.02% +0.0%
Public 59.57%59.33%59.31%59.85%59.85% +0.0%
No. of Shareholders 11,12110,77710,2409,9399,572 -3.7%

⚖️ Peer comparison

Industry: Healthcare · 22 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 VIJAYA Vijaya Diagnostic ₹1,507.80 15,530 82.7 857 187 42.3% 21.8% 19.5% 20.2% 22.8% 37.3%
2 METROPOLIS Metropolis Healthcare ₹596.30 12,370 61.1 1,710 203 24.7% 11.9% 23.6% 31.4% 16.6% 25.7%
3 HCG Healthcare Global ₹704.05 10,512 390.9 2,626 33 18.2% 1.3% 14.6% -53.3% 13.1% 175.3%
4 YATHARTH Yatharth Hospital ₹988.90 9,528 54.1 1,200 171 23.6% 14.3% 36.2% 31.6% 47.6% 16.2%
5 JLHL Jupiter Life ₹277.85 9,109 9.7 1,557 187 22.1% 12.0% 20.9% -6.7% 18.2% -14.5%
6 THYROCARE Thyrocare Technologies ₹555.45 8,841 50.0 876 176 32.1% 20.1% 20.8% 79.4% 24.3% 33.2%
7 KOVAI Kovai Medical ₹6,260.50 6,850 26.7 1,644 256 27.9% 15.6% 15.7% 16.7% 15.3% 20.6%
8 INDRAMEDCO Indraprastha Medical ₹363.20 3,330 17.7 1,524 188 18.0% 12.4% 9.3% 13.7% 11.3% 9.5%
9 KRSNAA Krsnaa Diagnostics ₹543.40 1,763 18.1 816 98 26.8% 12.0% 7.8% 31.0% 22.1% -19.3%
10 SURAKSHA Suraksha Diagnostic ₹311.85 1,624 45.3 325 35 31.4% 10.8% 23.1% 1.4% 20.7% 40.0%
11 SHALBY Shalby ₹132.15 1,418 38.0 1,176 37 12.1% 3.2% 5.0% 1683.0% 11.7% 36.7%
12 GPTHEALTH GPT Healthcare ₹157.90 1,296 27.4 491 48 18.5% 9.8% 15.1% -21.9% 17.8% 62.5%
13 LAXMIDENTL Laxmi Dental ₹196.21 1,080 35.0 287 31 16.2% 10.9% 16.0% -10.1% 13.2% 28.9%
14 NEPHROCARE Nephro Care ₹234.80 387 — — — — — — — 68.4% 347.7%
15 LOTUSEYE Lotus Eye ₹114.50 243 n/m 57 0 8.5% 0.3% 8.4% -89.1% 26.2% 13.0%
16 UNIHEALTH Unihealth Hospitals ₹121.00 190 6.5 132 46 40.9% 34.8% — — 104.6% 71.5%
17 MADHAVBAUG Vaidya Sane ₹148.00 156 19.1 147 8 11.4% 5.6% — — 116.1% 94.3%
18 MHHL Mohini Health ₹57.05 104 — 145 -17 -1.4% -11.7% — — -6.6% -1400.0%
19 MAITREYA Maitreya Medicare ₹120.65 82 — 45 -2 -1.0% -5.5% — — -5.2% -1720.0%
20 AATMAJ Aatmaj Healthcare ₹26.75 60 83.6 24 1 9.7% 2.9% — — 22.5% -39.4%
21 NIDAN Nidan Laborator. ₹33.00 46 30.6 26 2 19.0% 5.9% — — -11.2% -92.0%
22 ARTEMISMED Artemis Medicare ₹315.00 — 48.0 1,081 103 17.4% 9.6% 15.4% 25.9% 16.3% 30.9%
❓ Frequently asked questions
What was Lotus Eye Hospital and Institute Limited's revenue in Q1 FY27?
Lotus Eye Hospital and Institute Limited reported revenue of ₹17 crore for the quarter ended June 2026 (Q1 FY27).
What was Lotus Eye Hospital and Institute Limited's net profit in Q1 FY27?
Net profit stood at ₹1 crore. Earnings per share (EPS) came in at ₹0.30.
What is LOTUSEYE's market capitalisation and P/E ratio?
At the current price of ₹114.36, LOTUSEYE has a market capitalisation of ₹243 crore.
Who owns Lotus Eye Hospital and Institute Limited? (shareholding pattern)
As of Sep 2026, promoters held 40.14%, domestic institutional investors (DIIs) 0.02%, public shareholders 59.85% of Lotus Eye Hospital and Institute Limited.
TTM ends N/A. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI